EuroBiotech Report—Brexit, Boehringer, Therachon, Cellectis and Sensyne

Europe
(CC0 Public Domain)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week in the U.K., where the government published details of how it expects Brexit to affect drug developers. The missives talked up the prospect of negotiators agreeing to maintain something like the status quo continuing for the next few years, and said little about what will happen if talks break down. Elsewhere, the companies that will be affected by the changes continued to get on with business. Boehringer Ingelheim secured an option on a cystic fibrosis gene therapy. Therachon raised $60 million to run rare disease clinical trials. Cellectis poached an executive from Novartis. AI startup Sensyne Health filed to go public. And more.Nick Taylor  

1. U.K. commits to adopt EU trial regulation, minimize divergence after Brexit

The U.K. regulatory agency has detailed how it expects Brexit to affect its clinical trial regulations. Officials reiterated their intent for the U.K. to implement the incoming European Union Clinical Trials Regulation (CTR) and expanded on the long-term effects of Brexit on research approval processes.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

2. Boehringer Ingelheim lands option on cystic fibrosis gene therapy

Boehringer Ingelheim has secured the option to license a cystic fibrosis gene therapy. The agreement will see Boehringer work with British academics and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based gene therapy treatment for cystic fibrosis.

3. Novo powers rare disease startup Therachon to $60M round

Therachon has raised $60 million (€52 million) to take a phase 1 rare disease drug deeper into the clinic. The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.

4. CAR-T player Cellectis poaches Stefan Scherer from Novartis

Cellectis has named Stefan Scherer, M.D., Ph.D., as its SVP of clinical development. Scherer joins the off-the-shelf CAR-T pioneer from Novartis, where he headed up U.S. oncology early development and strategy.

5. AI data miner Sensyne Health looks to go public with $77M listing

Digital health company Sensyne Health announced plans to go public with a £60 million listing ($77 million) on the alternative investment market of the London Stock Exchange on Aug. 17.

And more articles of note>>